Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Anna, Couvillon"'
Autor:
Harpreet Singh, Seth Steinberg, Lisa Cordes, Helen Owens, Amy Hankin, Anna Couvillon, Marc R Theoret, Munjid Al-Harthy, Inger I Rosner, Philip M Arlen, Moniquea Williams, Sarah E Lochrin, Cindy H Chau, William Douglas Figg, William Dahut
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background The standard treatment for non-metastatic castration sensitive prostate cancer (nmCSPC) is androgen deprivation therapy (ADT) or surveillance. This study evaluated the potential synergy of immunotherapy and enzalutamide (without ADT) in nm
Externí odkaz:
https://doaj.org/article/ef49fdba74d849a0ab9d4e9c35ca2842
Autor:
Fatima Karzai, David VanderWeele, Ravi A. Madan, Helen Owens, Lisa M. Cordes, Amy Hankin, Anna Couvillon, Erin Nichols, Marijo Bilusic, Michael L. Beshiri, Kathleen Kelly, Venkatesh Krishnasamy, Sunmin Lee, Min-Jung Lee, Akira Yuno, Jane B. Trepel, Maria J. Merino, Ryan Dittamore, Jennifer Marté, Renee N. Donahue, Jeffrey Schlom, Keith J. Killian, Paul S. Meltzer, Seth M. Steinberg, James L. Gulley, Jung-Min Lee, William L. Dahut
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Abstract Background Checkpoint inhibitors have not been effective for prostate cancer as single agents. Durvalumab is a human IgG1-K monoclonal antibody that targets programmed death ligand 1 and is approved by the U.S. Food and Drug Administration f
Externí odkaz:
https://doaj.org/article/0cf7309b04d14ab6b60eafc1dd43beb1
Autor:
Ravi A Madan, Marijo Bilusic, Mark N Stein, Renee N Donahue, Philip M Arlen, Fatima Karzai, Elizabeth Plimack, Yu-Ning Wong, Daniel M Geynisman, Matthew Zibelman, Tina Mayer, Julius Strauss, Gang Chen, Myrna Rauckhorst, Sheri McMahon, Anna Couvillon, Seth Steinberg, William D Figg, William L Dahut, Jeffrey Schlom, James L Gulley
Publikováno v:
Oncologist
Background Before 2018, there was no standard of care for non-metastatic (M0) castration resistant prostate cancer nmCRPC. Androgen receptor antagonists (ARAs) were commonly used sequentially nmCRPC. Methods This was a multicenter, randomized clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f42ae97eefbd0c6b18ed912192756d91
https://europepmc.org/articles/PMC10322134/
https://europepmc.org/articles/PMC10322134/
Autor:
William L. Dahut, Peter A. Pinto, Baris Turkbey, Adam G. Sowalsky, James L. Gulley, Peter L. Choyke, Huihui Ye, Rosina T. Lis, Monique N. Williams, Amy Hankin, Anna Couvillon, Marijo Bilusic, Guinevere Chun, Nicolas T. Terrigino, John R. Bright, Nicole V. Carrabba, Lisa M. Cordes, David J. VanderWeele, Stephanie A. Harmon, Maria J. Merino, Joanna H. Shih, Ravi A. Madan, Scott Wilkinson, Stephanie M. Walker, Fatima Karzai
Purpose:For high-risk prostate cancer, standard treatment options include radical prostatectomy (RP) or radiotherapy plus androgen deprivation therapy (ADT). Despite definitive therapy, many patients will have disease recurrence. Imaging has the pote
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::147815514508cff24531e08dafbe01b8
https://doi.org/10.1158/1078-0432.c.6530054.v1
https://doi.org/10.1158/1078-0432.c.6530054.v1
Autor:
William L. Dahut, Peter A. Pinto, Baris Turkbey, Adam G. Sowalsky, James L. Gulley, Peter L. Choyke, Huihui Ye, Rosina T. Lis, Monique N. Williams, Amy Hankin, Anna Couvillon, Marijo Bilusic, Guinevere Chun, Nicolas T. Terrigino, John R. Bright, Nicole V. Carrabba, Lisa M. Cordes, David J. VanderWeele, Stephanie A. Harmon, Maria J. Merino, Joanna H. Shih, Ravi A. Madan, Scott Wilkinson, Stephanie M. Walker, Fatima Karzai
Contains supplementary methods and 3 supplementary tables.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c82bd18270832837c86305bdfe9f7e9
https://doi.org/10.1158/1078-0432.22478822
https://doi.org/10.1158/1078-0432.22478822
Autor:
Baris Turkbey, Peter A. Pinto, Joanna H. Shih, Maria Merino, Peter L. Choyke, Ravi A. Madan, John R. Bright, Stephanie Harmon, Guinevere Chun, Fatima Karzai, Huihui Ye, Amy Hankin, Scott Wilkinson, Anna Couvillon, Marijo Bilusic, Lisa M. Cordes, Nicolas T. Terrigino, David J. VanderWeele, Rosina T. Lis, William L. Dahut, Nicole V. Carrabba, Stephanie M. Walker, Monique N. Williams, James L. Gulley, Adam G. Sowalsky
Publikováno v:
Clin Cancer Res
Purpose: For high-risk prostate cancer, standard treatment options include radical prostatectomy (RP) or radiotherapy plus androgen deprivation therapy (ADT). Despite definitive therapy, many patients will have disease recurrence. Imaging has the pot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be83f295e4113b092f409dad8bd9797e
https://doi.org/10.1158/1078-0432.ccr-20-2344
https://doi.org/10.1158/1078-0432.ccr-20-2344
Autor:
Veda N. Giri, Laura Gross, Rebecca Hartman, Amy Leader, Young E. Whang, Anna Couvillon, Heather H. Cheng, Channing Judith Paller, Stacy Loeb, Lawrence Ivan Karsh, Sue J. Friedman, Tomasz M. Beer, Alexandra Sokolova, Scott W. Keith
Publikováno v:
Journal of Clinical Oncology. 41:128-128
128 Background: Indications for prostate cancer (PCA) germline testing (GT) have greatly expanded, with genetics delivery being implemented in a variety of ways. Here we evaluate factors related to men’s experience with genetic evaluation (GE) in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::241be2291b82be1d77d806754ded8b34
https://doi.org/10.1200/jco.2023.41.6_suppl.128
https://doi.org/10.1200/jco.2023.41.6_suppl.128
Autor:
Anna Couvillon, Baris Turkbey, Peter L. Choyke, Katherine Lee-Wisdom, Yolanda McKinney, Robert Sidlow, Michael P. Mullane, Veda N. Giri, Todd Matthew Morgan, Heather H. Cheng, Maria J. Merino, William Douglas Figg, Peter A. Pinto, William L. Dahut, Fatima Karzai
Publikováno v:
Journal of Clinical Oncology. 41:390-390
390 Background: PCa has inherited risk factors including high genetic risk variants such as BRCA1/2, HOXB13, and DNA mismatch repair genes. mpMRI has been shown to be effective for detection and staging of localized PCa. This study follows participan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c16d402381723be3c38899fe933dd67
https://doi.org/10.1200/jco.2023.41.6_suppl.390
https://doi.org/10.1200/jco.2023.41.6_suppl.390
Publikováno v:
Urology. 156
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a787df67515a56f477ece3f48c43748
https://pubmed.ncbi.nlm.nih.gov/34280438
https://pubmed.ncbi.nlm.nih.gov/34280438
Autor:
Mohammad O. Atiq, Shruti U. Gandhy, Fatima Karzai, Munjid Al Harthy, Gang Chen, Marijo Bilusic, David James VanderWeele, Elias Bin Aris Chandran, Lisa M. Cordes, Helen Owens, Anna Couvillon, Amy Hankin, Monique Williams, William Douglas Figg, Peter L. Choyke, Liza Lindenberg, Esther Mena, William L. Dahut, James L. Gulley, Ravi Amrit Madan
Publikováno v:
Journal of Clinical Oncology. 40:e17046-e17046
e17046 Background: Multiple treatment options combined with androgen deprivation therapy (ADT) provide a survival advantage in mCSPC. In this prospective study, mCSPC patients were treated with docetaxel and Prostvac, a therapeutic cancer vaccine. Si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25d6ee283b5b04f16501721081298bb7
https://doi.org/10.1200/jco.2022.40.16_suppl.e17046
https://doi.org/10.1200/jco.2022.40.16_suppl.e17046